03/16/23 6:30 AMNasdaq : NUVL earningsNuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline and business progress and fourth quarter and full year 2022 financial results. "2022 was a remarkable year of progress for Nuvalent. The team continued to execute through...RHEA-AIvery positive
03/14/23 5:59 PMNasdaq : NUVL conferencesclinical trialNuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655. The poster will be archived on the Nuvalent...RHEA-AIneutral
03/01/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Participate in the 43rd Annual Cowen Healthcare ConferenceNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 43 rd Annual Cowen Healthcare...RHEA-AIneutral
01/04/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will presentRHEA-AIneutral
12/13/22 10:15 AMNasdaq : NUVL Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating preciselyRHEA-AIneutral
11/10/22 6:30 AMNasdaq : NUVL earningsNuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial ResultsPreliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive NSCLCEnrollment progressing in ALKOVE-1 Phase 1/2 trial with parallel-lead candidate, NVL-655, for ALK-positiveRHEA-AIneutral
11/03/22 8:13 PMNasdaq : NUVL offeringNuvalent Announces Closing of Upsized Public Offering of Common StockNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwrittenRHEA-AIneutral
10/31/22 9:14 PMNasdaq : NUVL offeringNuvalent Announces Pricing of Public Offering of Common StockNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its previously announced underwritten publicRHEA-AIneutral
10/31/22 7:15 AMNasdaq : NUVL offeringNuvalent Announces Public Offering of Common StockNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering of $200.0RHEA-AIneutral
10/28/22 12:01 AMNasdaq : NUVL clinical trialNuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLCFavorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities, treatment-related serious adverse events, treatment- related dizziness, or adverse events leading to treatment reductions or discontinuations as ofRHEA-AIneutral